Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06095531
Other study ID # DVAL 21011
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 18, 2024
Est. completion date March 30, 2025

Study information

Verified date June 2024
Source RevBio
Contact Brian Hess
Phone 617-460-6675
Email bhess@revbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical pilot study will evaluate the use of a bioresorbable bone adhesive to improve cranial flap fixation at two study time points (at the time of fixation and 6 months). The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite for Cranial Flap Fixation (TN-CFF) to allow clinical study of the TN-CFF device in a greater number of patients.


Description:

The primary endpoint is safety during the post procedure follow up period. This endpoint will be evaluated through the rate of all serious adverse device and procedure related effects from the time of fixation to 6 months post-procedure. The secondary endpoints include efficacy evaluated through radiolucency data using CT imaging at the cranial flap cut lines and the change of radiolucency with respect to time, device related adverse events, flap immobility at time of fixation, six months and 12 months, evaluation of flap translation and patient reported outcome measures.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures. - Subjects can be any gender, but be between (and including) 18 and 75 years of age - Subject is scheduled for a cranial procedure in the supratentorial location. - Subject requires a procedure involving a Class I/clean wound (uninfected surgical wound in which no inflammation was encountered). - Subject, and/or subject's family are able and willing to provide informed consent and HIPAA authorization. - Subject is able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests. Intra-Operative Inclusion Criteria: - Width of craniotomy kerf line < 3mm for more than 75% of the bone flap border Exclusion Criteria: - Subject requires a procedure involving a translabyrinthine, transsphenoidal, transoral approach, or any procedure that penetrates the air sinus or mastoid air cells. Note: Superficial penetration of mastoid air cells is not an exclusion if cells were appropriately sealed (e.g., bone wax). - Subject has clinically significant hydrocephalus or clinical evidence of altered CSF dynamics. - Subject has undergone a previous, open intracranial neurosurgical procedure in the same anatomical location. (Note: stereotactic biopsy was not exclusionary). - Subject requires a craniectomy (the bone flap is not replaced during the current surgery). - Subject had radiation treatment to the surgical site, or standard fractionated radiation therapy was planned post index-procedure. (Note: stereotactic radiosurgery prior to the planned index procedure was not an exclusion criterion.) - Subject has a condition with anticipated survival shorter than six months. - Subject has undergone chemotherapy treatment, excluding hormonal therapy, within three weeks prior to the planned index procedure, or use of intracavitary chemotherapy wafer (BCNU) was planned, or chemotherapy treatment was planned within two weeks after the index procedure was performed. - Standard use of peri-operative steroids (i.e., corticosteroids) is permitted. Chronic steroid use (defined as daily use of corticosteroids for = 8 weeks) for the purposes of reducing the side effects of chemotherapy and/or radiation therapy for cancer is not exclusionary unless the patient is deemed by the investigator to be suffering from steroid toxicity (i.e., Cushing's syndrome) manifested by symptoms and signs such as thin skin, striae, easy bruising, muscle atrophy, upper body obesity, severe fatigue, etc. Use of corticosteroids on a chronic basis (as defined previously) for purposes other than decreasing the symptoms of systemic chemotherapy is exclusionary unless those steroids were discontinued 4 weeks prior to the planned index procedure. - Subject receives warfarin, heparin, other anticoagulant agents on a daily basis and pre-surgical, standard of care drug wash-out did not occur. - Subject is pregnant, breast-feeding, or intended to become pregnant during the course of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Tetranite for Cranial Flap Fixation (TN-CFF)
Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts
United States Semmes Murphey Clinic Memphis Tennessee

Sponsors (1)

Lead Sponsor Collaborator
RevBio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Neurological Exam using the Karnofsky Performance Scale (KPS) Neurological exam will be completed throughout the study to assess neurological healing. The KPS scale is designed to measure the level of patient activity and medical care requirements Throughout 12 Months post-procedure period
Other Neurological Exam using the Neurologic Assessment in Neuro-Oncology (NANO) scale. Neurological exams will be completed throughout the study to assess neurological healing. The NANO scale is a quantifiable evaluation of 9 relevant neurologic domains based on direct observation and testing conducted during routine office visits. Throughout 12 Months post-procedure period
Other Wound healing will be evaluated at post-surgical visits and will result in one of the three results: Surgical Revision needed, Superficial dehiscence, Completely Healed. All post-surgical visits will include a wound assessment. The assessment will be conducted through a choice of 3 options: Surgical Revision needed, Superficial dehiscence, Completely Healed. Throughout 12 Months post-procedure period
Other Patient reported outcomes will also be measured using a patient taken picture of surgical wound. A patient taken picture of surgical wound will be taken to show wound progress. Throughout 12 Months post-procedure period
Other Patient Reported Outcome using a Cranio-facial assessment survey. Subject satisfaction after TN-CFF was used for cranial flap fixation using a questionnaire for overall quality of life measures. Throughout 12 Months post-procedure period
Other Qualitative assessment of artifact and distortion of MRIs. Assessment of artifact and distortion on MRIs (for cases when imaging is available) Throughout 12 Months post-procedure period
Primary The primary endpoint is the rate of all serious adverse device and procedure related effects during the post procedure follow up period. Rate of all serious adverse device and procedure related effects from the time of fixation to 6 months post - procedure Time of fixation and 6 months post-procedure
Secondary Radiolucency data using CT imaging at the cranial flap cut lines. Radiolucency data using CT imaging at the cranial flap cut lines and the change of radiolucency with respect to time. Throughout 12 Months post-procedure period
Secondary Change in radiolucency using CT imaging at the cranial flap cut lines with respect to time. Radiolucency data using CT imaging at the cranial flap cut lines and the change of radiolucency with respect to time Throughout 12 Months post-procedure period
Secondary Device-related adverse events. Device-related adverse events included all adverse events classified as definitely, probably, possibly, or undetermined relation to the device or procedure. Throughout 12 Months post-procedure period
Secondary Flap immobility determined clinical palpation of the cranial flap by an independent neurosurgeon. Flap immobility will be determined by an independent neurosurgeon. Time of fixation and 6 months post-procedure
Secondary Flap immobility at 6 months and 12 months determined by clinical palpation of the cranial flap by the neurosurgeon and the patient. Flap immobility will be determined by the surgeon and the patient. 6 months and 12 months post-procedure
Secondary Translation of the flap based on CT scan. Translation of the flap based on CT scan Throughout 12 Months post-procedure period
Secondary Patient Reported outcome using PROMIS10. Subject satisfaction after TN-CFF was used for cranial flap fixation using a validated questionnaire for overall health. Throughout 12 Months post-procedure period
Secondary Patient Reported outcome using the 36 Item Short Form Survey (SF-36). Subject satisfaction after TN-CFF was used for cranial flap fixation using a validated questionnaire for overall quality of life measures. Throughout 12 Months post-procedure period
Secondary Patient Reported outcome as measured on a Visual Analog Scale of pain intensity. Subject satisfaction after TN-CFF is used for cranial flap fixation (i.e., level of headache pain) Throughout 12 Months post-procedure period
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02880566 - Efficacy of Scalp Block on Hemodynamic Stability and Opioid Consumption During Craniotomy N/A
Completed NCT05103735 - Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
Completed NCT04285359 - Impact of Severe Intraoperative Hyperglycemia on Infection Rate After Elective Intracranial Interventions
Completed NCT03364283 - Sitting Versus Horizontal Position on Craniotomies
Completed NCT01502540 - Pain Prevalence After Major Craniotomy N/A
Recruiting NCT06157359 - Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection N/A
Recruiting NCT01474304 - Intravenous Acetaminophen for Craniotomy Patients Phase 2
Completed NCT01617837 - The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy Phase 2/Phase 3
Recruiting NCT04229966 - Prospective, Observational Real-world Treatments of AEDH in Large-scale Surgical Cases
Completed NCT01987648 - eCRANIO Trial Study on Elective CRAniotomies: Postoperative Neurointensive Care, Imaging and Outcome
Recruiting NCT05962684 - A Greek-designed ERAS Protocol in Elective Craniotomy
Recruiting NCT04261673 - Prospective Randomized Evaluation of Decompressive Ipsilateral Craniectomy for Traumatic Acute Epidural Hematoma N/A
Completed NCT05940935 - The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
Completed NCT03033706 - Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy N/A
Completed NCT00658242 - Craniofacial Surgery Perioperative Registry N/A
Completed NCT04859907 - Bone Flap Fixation Systems For Craniotomy Procedures N/A
Active, not recruiting NCT02237716 - Rapid Intravenous Infusion of Mannitol Results in a Dipper-type Change in Stroke Volume Variation in Patients Undergoing Major Neurosurgery N/A
Recruiting NCT01966939 - Influences of Types of Skull Surgery on Temporomandibular Joint Performance N/A
Completed NCT01606969 - Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution N/A
Completed NCT00590499 - Agitation in Post Operative Neurosurgical Patients N/A